• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Assessing Naltrexone Prescribing and Barriers to Initiation for Alcohol Use Disorder: A Multidisciplinary, Multisite Survey.评估纳曲酮用于酒精使用障碍的处方开具情况及起始治疗的障碍:一项多学科、多地点调查。
Front Psychiatry. 2022 May 10;13:856938. doi: 10.3389/fpsyt.2022.856938. eCollection 2022.
2
Survey of Addiction Specialists' Use of Medications to Treat Alcohol Use Disorder.成瘾专家使用药物治疗酒精使用障碍的调查。
Front Psychiatry. 2020 Feb 14;11:47. doi: 10.3389/fpsyt.2020.00047. eCollection 2020.
3
Analysis of Ohio Advanced Practice Registered Nurses' Rate of Prescribing Naltrexone for Patients With Alcohol Use Disorder Since Elimination of the X-Waiver.自取消X豁免以来俄亥俄州高级执业注册护士为酒精使用障碍患者开具纳曲酮的比例分析
J Am Psychiatr Nurses Assoc. 2025 Jun;31(3):259-266. doi: 10.1177/10783903241271273. Epub 2024 Aug 18.
4
National Provider Survey: Use of Naltrexone for Pregnant Individuals with Substance Use Disorders.国家提供者调查:纳曲酮在患有物质使用障碍的孕妇中的使用。
J Addict Med. 2023;17(6):736-738. doi: 10.1097/ADM.0000000000001225. Epub 2023 Sep 20.
5
Presence of opioid safety initiatives, prescribing patterns for opioid and naloxone, and perceived barriers to prescribing naloxone: Cross-sectional survey results based on practice type, scope, and location.阿片类药物安全措施的存在、阿片类药物和纳洛酮的处方模式,以及开具纳洛酮的感知障碍:基于实践类型、范围和地点的横断面调查结果。
J Opioid Manag. 2021 Jan-Feb;17(1):19-38. doi: 10.5055/jom.2021.0611.
6
A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices.一项比较美国基层医疗实践中医生报告的使用丁丙诺啡和纳曲酮治疗成瘾的障碍的定性研究。
Int J Drug Policy. 2018 Apr;54:9-17. doi: 10.1016/j.drugpo.2017.11.021. Epub 2018 Jan 8.
7
Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.一项扩大阿片类药物使用障碍治疗药物治疗处方者的劳动力发展干预措施的测试:一项群组随机试验的方案。
Implement Sci. 2017 Nov 15;12(1):135. doi: 10.1186/s13012-017-0665-x.
8
Prescribing attitudes of different physician groups regarding fluoxetine.不同医生群体对氟西汀的处方态度。
Ann Pharmacother. 1993 Dec;27(12):1443-7. doi: 10.1177/106002809302701204.
9
Research to practice: adoption of naltrexone in alcoholism treatment.从研究到实践:纳曲酮在酒精使用障碍治疗中的应用
J Subst Abuse Treat. 2003 Jan;24(1):1-11.
10
Very Low Frequency of Drug Therapy of Alcohol Dependence in Germany - Analysis of Data of A Statutory Health Insurance.德国酒精依赖药物治疗的极低频率——法定健康保险数据分析。
Pharmacopsychiatry. 2020 Jan;53(1):37-39. doi: 10.1055/a-0896-2757. Epub 2019 May 27.

引用本文的文献

1
Things We Do for No Reason™: Avoiding naltrexone for alcohol use disorder in liver disease.我们无端为之的事情™:肝病患者酒精使用障碍时避免使用纳曲酮
J Hosp Med. 2025 Jul;20(7):768-771. doi: 10.1002/jhm.13569. Epub 2024 Dec 10.
2
Promoting alcohol treatment engagement post-hospitalization with brief intervention, medications and CBT4CBT: protocol for a randomized clinical trial in a diverse patient population.以简短干预、药物和 CBT4CBT 促进住院后酒精治疗参与:在多样化患者群体中进行的随机临床试验方案。
Addict Sci Clin Pract. 2023 Sep 19;18(1):55. doi: 10.1186/s13722-023-00407-9.
3
Alcohol Use Disorder Treatment in Sexually and Gender Diverse Patients: A Retrospective Cohort Study.性与性别多样化患者的酒精使用障碍治疗:一项回顾性队列研究。
J Clin Psychiatry. 2023 Aug 28;84(5):23m14812. doi: 10.4088/JCP.23m14812.

本文引用的文献

1
Naltrexone Initiation in the Inpatient Setting for Alcohol Use Disorder: A Systematic Review of Clinical Outcomes.住院环境中用于酒精使用障碍的纳曲酮起始治疗:临床结局的系统评价
Mayo Clin Proc Innov Qual Outcomes. 2021 Apr 8;5(2):495-501. doi: 10.1016/j.mayocpiqo.2021.01.013. eCollection 2021 Apr.
2
The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update.美国成瘾医学协会阿片类物质使用障碍治疗国家实践指南:2020年重点更新
J Addict Med. 2020 Mar/Apr;14(2S Suppl 1):1-91. doi: 10.1097/ADM.0000000000000633.
3
Survey of Addiction Specialists' Use of Medications to Treat Alcohol Use Disorder.成瘾专家使用药物治疗酒精使用障碍的调查。
Front Psychiatry. 2020 Feb 14;11:47. doi: 10.3389/fpsyt.2020.00047. eCollection 2020.
4
Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA.美国治疗酒精和阿片类药物使用障碍的药物供应情况。
Neurotherapeutics. 2020 Jan;17(1):55-69. doi: 10.1007/s13311-019-00814-4.
5
Implementing alcohol use disorder pharmacotherapy in primary care settings: a qualitative analysis of provider-identified barriers and impact on implementation outcomes.在基层医疗环境中实施酒精使用障碍药物治疗:对提供者确定的障碍及其对实施结果的影响的定性分析。
Addict Sci Clin Pract. 2019 Jul 10;14(1):24. doi: 10.1186/s13722-019-0151-7.
6
Naltrexone effects on subjective responses to alcohol in the human laboratory: A systematic review and meta-analysis.纳曲酮对人体实验室中酒精主观反应的影响:系统评价和荟萃分析。
Addict Biol. 2019 Nov;24(6):1138-1152. doi: 10.1111/adb.12747. Epub 2019 May 30.
7
Barriers to and Facilitators of Alcohol Use Disorder Pharmacotherapy in Primary Care: A Qualitative Study in Five VA Clinics.初级保健中酒精使用障碍药物治疗的障碍和促进因素:在五家退伍军人事务诊所进行的定性研究。
J Gen Intern Med. 2018 Mar;33(3):258-267. doi: 10.1007/s11606-017-4202-z. Epub 2017 Oct 30.
8
Daily relations among affect, urge, targeted naltrexone, and alcohol use in young adults.年轻人中情感、冲动、靶向纳曲酮与酒精使用之间的日常关系。
Exp Clin Psychopharmacol. 2016 Oct;24(5):367-375. doi: 10.1037/pha0000090.
9
Reductions in Alcohol Craving Following Naltrexone Treatment for Heavy Drinking.纳曲酮治疗重度饮酒后酒精渴望的降低
Alcohol Alcohol. 2016 Sep;51(5):562-6. doi: 10.1093/alcalc/agw038. Epub 2016 Jul 11.
10
Naltrexone: A Pan-Addiction Treatment?纳曲酮:一种泛成瘾治疗方法?
CNS Drugs. 2016 Aug;30(8):719-33. doi: 10.1007/s40263-016-0373-0.

评估纳曲酮用于酒精使用障碍的处方开具情况及起始治疗的障碍:一项多学科、多地点调查。

Assessing Naltrexone Prescribing and Barriers to Initiation for Alcohol Use Disorder: A Multidisciplinary, Multisite Survey.

作者信息

Leung Jonathan G, Narayanan Prasanna P, Markota Matej, Miller Nathaniel E, Philbrick Kemuel L, Burton M Caroline, Kirchoff Robert W

机构信息

Pharmacy Services, Mayo Clinic, Rochester, MN, United States.

Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States.

出版信息

Front Psychiatry. 2022 May 10;13:856938. doi: 10.3389/fpsyt.2022.856938. eCollection 2022.

DOI:10.3389/fpsyt.2022.856938
PMID:35619618
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9127043/
Abstract

OBJECTIVE

To survey barriers in prescribing naltrexone for alcohol use disorder.

METHODS

A 12-question survey related to naltrexone prescribing patterns, perceptions, and knowledge was sent to 770 prescribers in the departments of internal medicine, family medicine, and psychiatry across a health system with sites in Arizona, Florida, and Minnesota.

RESULTS

Responses were obtained and included for 146/770 prescribers (19.0% response rate). Most respondents were in the department of internal medicine ( = 94, 64.4%), but the departments of psychiatry ( = 22, 15.1%) and family medicine ( = 30, 20.5%) were also represented. Only 34 (23.3%) respondents indicated they had prescribed naltrexone in the previous 3 months. The most common reasons for not prescribing naltrexone were "unfamiliarity with naltrexone for treatment of alcohol use disorder" and "patients do not have appropriate follow-up or are not in a formal treatment program." Compared with those representing internal/family medicine, psychiatry respondents were more likely to prescribe naltrexone and answer knowledge questions correctly.

CONCLUSION

In this survey among primarily non-addiction-trained prescribers, a disparity was shown for prescribing naltrexone and in knowledge barriers between staff in internal/family medicine and psychiatry. There exist opportunities for education and quality improvement that promote the prescribing of naltrexone for alcohol use disorder by non-addiction specialists.

摘要

目的

调查在开具纳曲酮治疗酒精使用障碍时存在的障碍。

方法

向亚利桑那州、佛罗里达州和明尼苏达州设有医疗点的一个医疗系统内的内科、家庭医学科和精神科的770名开处方者发送了一份与纳曲酮处方模式、认知和知识相关的12个问题的调查问卷。

结果

共获得146/770名开处方者的回复(回复率为19.0%)。大多数受访者来自内科(n = 94,64.4%),精神科(n = 22,15.1%)和家庭医学科(n = 30,20.5%)也有代表。只有34名(23.3%)受访者表示他们在过去3个月内开具过纳曲酮。不开具纳曲酮的最常见原因是“不熟悉纳曲酮治疗酒精使用障碍”以及“患者没有适当的随访或未参加正规治疗项目”。与内科/家庭医学科的受访者相比,精神科受访者更有可能开具纳曲酮并正确回答知识问题。

结论

在这项主要针对未接受成瘾治疗培训的开处方者的调查中,在内科/家庭医学科和精神科工作人员之间,纳曲酮的处方情况以及知识障碍方面存在差异。存在通过教育和质量改进来促进非成瘾专科医生开具纳曲酮治疗酒精使用障碍的机会。